Pharma BD Deal Intelligence
AstraZeneca acquired Gracell Biotechnologies for $1.2B for cell therapy.
AstraZeneca completes acquisition of Gracell Biotechnologies: $2.00/share cash (~$1.0bn upfront) plus a $0.30/share CVR on a regulatory milestone…
AstraZeneca bolsters cellular therapy pipeline with acquisition of Gracell Biotechnologies and its FasTCAR-enabled technology platform.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
AstraZeneca acquired Nasdaq-listed, China-headquartered clinical-stage cell-therapy company Gracell Biotechnologies in a merger announced 26 December 2023 and completed 22 February 2024. Shareholders received $2.00 per ordinary share (or per ADS) in cash at closing -- an upfront transaction value of approximately $1.0 billion -- plus a non-tradable contingent value right (CVR) of $0.30 per share payable on achievement of a specified regulatory milestone, taking the total potential consideration to approximately $1.2 billion. The acquisition centred on GC012F (now AZD0120), a FasTCAR-enabled, dual-targeting (BCMA and CD19) autologous CAR-T therapy with next-day manufacturing, in development for relapsed/refractory multiple myeloma and B-cell-driven autoimmune disease including systemic lupus erythematosus. The deal expanded AstraZeneca's cell-therapy footprint and added China-based manufacturing and clinical capabilities.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Gracell Biotechnologies (this deal) | 2023 | $1.2B | 65 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2023 deals · AstraZeneca PLC deals · Oncology deals